A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis : results from the MSBase registry
What is this summary about?Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries.Using information from the MSBase registry, the GLIMPSE (Gen...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Spelman, Tim Ozakbas, Serkan Alroughani, Raed Terzi, Murat Hodgkinson, Suzanne Laureys, Guy Kalincik, Tomas Der Walt, Anneke Van Yamout, Bassem Lechner-Scott, Jeannette Soysal, Aysun Kuhle, Jens Sanchez-Menoyo, Jose Luis Morgado, Yolanda Blanco Spitaleri, Daniele LA Pesch, Vincent van Horakova, Dana Ampapa, Radek Patti, Francesco Macdonell, Richard Al-Asmi, Abdullah Gerlach, Oliver Oh, Jiwon Altintas, Ayse Tundia, Namita Wong, Schiffon L Butzkueven, Helmut MSBase Study Group, [missing] |
| description | What is this summary about?Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries.Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad((R))) compared with other oral treatments.What were the results?Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS.What do the results mean?The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS. |
| format | Article |
| fullrecord | <record><control><sourceid>ghent</sourceid><recordid>TN_cdi_ghent_librecat_oai_archive_ugent_be_01H3V8AC9XDZ3FP5W9ME0Y5XRP</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>oai_archive_ugent_be_01H3V8AC9XDZ3FP5W9ME0Y5XRP</sourcerecordid><originalsourceid>FETCH-ghent_librecat_oai_archive_ugent_be_01H3V8AC9XDZ3FP5W9ME0Y5XRP3</originalsourceid><addsrcrecordid>eNqtTk1Kw0AUzkLBor3Du0AhaRqauqs1pZtC0aLVTXiZviQD8xPemyg9jjd1FI_g6oPv_yqZZMuinM3T-eImmYroJs0W2aIslsUk-VrDYFA7MOi6ETsCGa1FvoB3EHoCaltSQX-QIxHwLSiDZ9aNdgQBG0NBQHk7INMZPnXowccYg2c0EJgwWHLR03oGO5qgBxM3lCH2ogXugUkiHQ3s7e_i_vkBhSLfaQl8uUuuWzRC0z-8TaptddzsZl0fi2ujGyaFofaoa2TVx6v12P1IDdVptstfyvVmdXp8z7eH4nW1r9K34vR0yP-r5xviwHYF</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis : results from the MSBase registry</title><source>Ghent University Academic Bibliography</source><source>PubMed Central</source><creator>Spelman, Tim ; Ozakbas, Serkan ; Alroughani, Raed ; Terzi, Murat ; Hodgkinson, Suzanne ; Laureys, Guy ; Kalincik, Tomas ; Der Walt, Anneke Van ; Yamout, Bassem ; Lechner-Scott, Jeannette ; Soysal, Aysun ; Kuhle, Jens ; Sanchez-Menoyo, Jose Luis ; Morgado, Yolanda Blanco ; Spitaleri, Daniele LA ; Pesch, Vincent van ; Horakova, Dana ; Ampapa, Radek ; Patti, Francesco ; Macdonell, Richard ; Al-Asmi, Abdullah ; Gerlach, Oliver ; Oh, Jiwon ; Altintas, Ayse ; Tundia, Namita ; Wong, Schiffon L ; Butzkueven, Helmut ; MSBase Study Group, [missing]</creator><creatorcontrib>Spelman, Tim ; Ozakbas, Serkan ; Alroughani, Raed ; Terzi, Murat ; Hodgkinson, Suzanne ; Laureys, Guy ; Kalincik, Tomas ; Der Walt, Anneke Van ; Yamout, Bassem ; Lechner-Scott, Jeannette ; Soysal, Aysun ; Kuhle, Jens ; Sanchez-Menoyo, Jose Luis ; Morgado, Yolanda Blanco ; Spitaleri, Daniele LA ; Pesch, Vincent van ; Horakova, Dana ; Ampapa, Radek ; Patti, Francesco ; Macdonell, Richard ; Al-Asmi, Abdullah ; Gerlach, Oliver ; Oh, Jiwon ; Altintas, Ayse ; Tundia, Namita ; Wong, Schiffon L ; Butzkueven, Helmut ; MSBase Study Group, [missing]</creatorcontrib><description>What is this summary about?Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries.Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad((R))) compared with other oral treatments.What were the results?Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS.What do the results mean?The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.</description><identifier>ISSN: 1758-2024</identifier><identifier>ISSN: 1758-2032</identifier><language>eng</language><publisher>Future Medicine Ltd</publisher><subject>cladribine tablets ; dimethyl fumarate (Tecfidera(& REG ; fingolimod (Gilenya(& REG ; lay summary ; Medicine and Health Sciences ; multiple sclerosis ; Neurology (clinical) ; relapses ; teriflunomide (Aubagio(& REG ; treatment options</subject><creationdate>2023</creationdate><rights>No license (in copyright) info:eu-repo/semantics/openAccess</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,315,776,780,4009,27839</link.rule.ids></links><search><creatorcontrib>Spelman, Tim</creatorcontrib><creatorcontrib>Ozakbas, Serkan</creatorcontrib><creatorcontrib>Alroughani, Raed</creatorcontrib><creatorcontrib>Terzi, Murat</creatorcontrib><creatorcontrib>Hodgkinson, Suzanne</creatorcontrib><creatorcontrib>Laureys, Guy</creatorcontrib><creatorcontrib>Kalincik, Tomas</creatorcontrib><creatorcontrib>Der Walt, Anneke Van</creatorcontrib><creatorcontrib>Yamout, Bassem</creatorcontrib><creatorcontrib>Lechner-Scott, Jeannette</creatorcontrib><creatorcontrib>Soysal, Aysun</creatorcontrib><creatorcontrib>Kuhle, Jens</creatorcontrib><creatorcontrib>Sanchez-Menoyo, Jose Luis</creatorcontrib><creatorcontrib>Morgado, Yolanda Blanco</creatorcontrib><creatorcontrib>Spitaleri, Daniele LA</creatorcontrib><creatorcontrib>Pesch, Vincent van</creatorcontrib><creatorcontrib>Horakova, Dana</creatorcontrib><creatorcontrib>Ampapa, Radek</creatorcontrib><creatorcontrib>Patti, Francesco</creatorcontrib><creatorcontrib>Macdonell, Richard</creatorcontrib><creatorcontrib>Al-Asmi, Abdullah</creatorcontrib><creatorcontrib>Gerlach, Oliver</creatorcontrib><creatorcontrib>Oh, Jiwon</creatorcontrib><creatorcontrib>Altintas, Ayse</creatorcontrib><creatorcontrib>Tundia, Namita</creatorcontrib><creatorcontrib>Wong, Schiffon L</creatorcontrib><creatorcontrib>Butzkueven, Helmut</creatorcontrib><creatorcontrib>MSBase Study Group, [missing]</creatorcontrib><title>A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis : results from the MSBase registry</title><description>What is this summary about?Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries.Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad((R))) compared with other oral treatments.What were the results?Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS.What do the results mean?The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.</description><subject>cladribine tablets</subject><subject>dimethyl fumarate (Tecfidera(& REG</subject><subject>fingolimod (Gilenya(& REG</subject><subject>lay summary</subject><subject>Medicine and Health Sciences</subject><subject>multiple sclerosis</subject><subject>Neurology (clinical)</subject><subject>relapses</subject><subject>teriflunomide (Aubagio(& REG</subject><subject>treatment options</subject><issn>1758-2024</issn><issn>1758-2032</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ADGLB</sourceid><recordid>eNqtTk1Kw0AUzkLBor3Du0AhaRqauqs1pZtC0aLVTXiZviQD8xPemyg9jjd1FI_g6oPv_yqZZMuinM3T-eImmYroJs0W2aIslsUk-VrDYFA7MOi6ETsCGa1FvoB3EHoCaltSQX-QIxHwLSiDZ9aNdgQBG0NBQHk7INMZPnXowccYg2c0EJgwWHLR03oGO5qgBxM3lCH2ogXugUkiHQ3s7e_i_vkBhSLfaQl8uUuuWzRC0z-8TaptddzsZl0fi2ujGyaFofaoa2TVx6v12P1IDdVptstfyvVmdXp8z7eH4nW1r9K34vR0yP-r5xviwHYF</recordid><startdate>2023</startdate><enddate>2023</enddate><creator>Spelman, Tim</creator><creator>Ozakbas, Serkan</creator><creator>Alroughani, Raed</creator><creator>Terzi, Murat</creator><creator>Hodgkinson, Suzanne</creator><creator>Laureys, Guy</creator><creator>Kalincik, Tomas</creator><creator>Der Walt, Anneke Van</creator><creator>Yamout, Bassem</creator><creator>Lechner-Scott, Jeannette</creator><creator>Soysal, Aysun</creator><creator>Kuhle, Jens</creator><creator>Sanchez-Menoyo, Jose Luis</creator><creator>Morgado, Yolanda Blanco</creator><creator>Spitaleri, Daniele LA</creator><creator>Pesch, Vincent van</creator><creator>Horakova, Dana</creator><creator>Ampapa, Radek</creator><creator>Patti, Francesco</creator><creator>Macdonell, Richard</creator><creator>Al-Asmi, Abdullah</creator><creator>Gerlach, Oliver</creator><creator>Oh, Jiwon</creator><creator>Altintas, Ayse</creator><creator>Tundia, Namita</creator><creator>Wong, Schiffon L</creator><creator>Butzkueven, Helmut</creator><creator>MSBase Study Group, [missing]</creator><general>Future Medicine Ltd</general><scope>ADGLB</scope></search><sort><creationdate>2023</creationdate><title>A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis : results from the MSBase registry</title><author>Spelman, Tim ; Ozakbas, Serkan ; Alroughani, Raed ; Terzi, Murat ; Hodgkinson, Suzanne ; Laureys, Guy ; Kalincik, Tomas ; Der Walt, Anneke Van ; Yamout, Bassem ; Lechner-Scott, Jeannette ; Soysal, Aysun ; Kuhle, Jens ; Sanchez-Menoyo, Jose Luis ; Morgado, Yolanda Blanco ; Spitaleri, Daniele LA ; Pesch, Vincent van ; Horakova, Dana ; Ampapa, Radek ; Patti, Francesco ; Macdonell, Richard ; Al-Asmi, Abdullah ; Gerlach, Oliver ; Oh, Jiwon ; Altintas, Ayse ; Tundia, Namita ; Wong, Schiffon L ; Butzkueven, Helmut ; MSBase Study Group, [missing]</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-ghent_librecat_oai_archive_ugent_be_01H3V8AC9XDZ3FP5W9ME0Y5XRP3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>cladribine tablets</topic><topic>dimethyl fumarate (Tecfidera(& REG</topic><topic>fingolimod (Gilenya(& REG</topic><topic>lay summary</topic><topic>Medicine and Health Sciences</topic><topic>multiple sclerosis</topic><topic>Neurology (clinical)</topic><topic>relapses</topic><topic>teriflunomide (Aubagio(& REG</topic><topic>treatment options</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Spelman, Tim</creatorcontrib><creatorcontrib>Ozakbas, Serkan</creatorcontrib><creatorcontrib>Alroughani, Raed</creatorcontrib><creatorcontrib>Terzi, Murat</creatorcontrib><creatorcontrib>Hodgkinson, Suzanne</creatorcontrib><creatorcontrib>Laureys, Guy</creatorcontrib><creatorcontrib>Kalincik, Tomas</creatorcontrib><creatorcontrib>Der Walt, Anneke Van</creatorcontrib><creatorcontrib>Yamout, Bassem</creatorcontrib><creatorcontrib>Lechner-Scott, Jeannette</creatorcontrib><creatorcontrib>Soysal, Aysun</creatorcontrib><creatorcontrib>Kuhle, Jens</creatorcontrib><creatorcontrib>Sanchez-Menoyo, Jose Luis</creatorcontrib><creatorcontrib>Morgado, Yolanda Blanco</creatorcontrib><creatorcontrib>Spitaleri, Daniele LA</creatorcontrib><creatorcontrib>Pesch, Vincent van</creatorcontrib><creatorcontrib>Horakova, Dana</creatorcontrib><creatorcontrib>Ampapa, Radek</creatorcontrib><creatorcontrib>Patti, Francesco</creatorcontrib><creatorcontrib>Macdonell, Richard</creatorcontrib><creatorcontrib>Al-Asmi, Abdullah</creatorcontrib><creatorcontrib>Gerlach, Oliver</creatorcontrib><creatorcontrib>Oh, Jiwon</creatorcontrib><creatorcontrib>Altintas, Ayse</creatorcontrib><creatorcontrib>Tundia, Namita</creatorcontrib><creatorcontrib>Wong, Schiffon L</creatorcontrib><creatorcontrib>Butzkueven, Helmut</creatorcontrib><creatorcontrib>MSBase Study Group, [missing]</creatorcontrib><collection>Ghent University Academic Bibliography</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Spelman, Tim</au><au>Ozakbas, Serkan</au><au>Alroughani, Raed</au><au>Terzi, Murat</au><au>Hodgkinson, Suzanne</au><au>Laureys, Guy</au><au>Kalincik, Tomas</au><au>Der Walt, Anneke Van</au><au>Yamout, Bassem</au><au>Lechner-Scott, Jeannette</au><au>Soysal, Aysun</au><au>Kuhle, Jens</au><au>Sanchez-Menoyo, Jose Luis</au><au>Morgado, Yolanda Blanco</au><au>Spitaleri, Daniele LA</au><au>Pesch, Vincent van</au><au>Horakova, Dana</au><au>Ampapa, Radek</au><au>Patti, Francesco</au><au>Macdonell, Richard</au><au>Al-Asmi, Abdullah</au><au>Gerlach, Oliver</au><au>Oh, Jiwon</au><au>Altintas, Ayse</au><au>Tundia, Namita</au><au>Wong, Schiffon L</au><au>Butzkueven, Helmut</au><au>MSBase Study Group, [missing]</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis : results from the MSBase registry</atitle><date>2023</date><risdate>2023</risdate><issn>1758-2024</issn><issn>1758-2032</issn><abstract>What is this summary about?Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries.Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad((R))) compared with other oral treatments.What were the results?Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS.What do the results mean?The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.</abstract><pub>Future Medicine Ltd</pub><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1758-2024 |
| ispartof | |
| issn | 1758-2024 1758-2032 |
| language | eng |
| recordid | cdi_ghent_librecat_oai_archive_ugent_be_01H3V8AC9XDZ3FP5W9ME0Y5XRP |
| source | Ghent University Academic Bibliography; PubMed Central |
| subjects | cladribine tablets dimethyl fumarate (Tecfidera(& REG fingolimod (Gilenya(& REG lay summary Medicine and Health Sciences multiple sclerosis Neurology (clinical) relapses teriflunomide (Aubagio(& REG treatment options |
| title | A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis : results from the MSBase registry |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T18%3A12%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-ghent&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20plain%20language%20summary%20on%20the%20effectiveness%20of%20cladribine%20tablets%20compared%20with%20other%20oral%20treatments%20for%20multiple%20sclerosis%20:%20results%20from%20the%20MSBase%20registry&rft.au=Spelman,%20Tim&rft.date=2023&rft.issn=1758-2024&rft_id=info:doi/&rft_dat=%3Cghent%3Eoai_archive_ugent_be_01H3V8AC9XDZ3FP5W9ME0Y5XRP%3C/ghent%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |